Portfolio Alerts Watch List Cart

Healthcare

Refine Search


Product Compare (0)
B
Boston Bio Systems Ltd
Score 48/100• Risky
Boston Bio Systems Ltd presents several risks with inconsistent growth and profitability metrics, making it a risky investment at this time.
Company’s Health42/100
Valuation 80/100 · PB 1.0085
Technical Avoid
1M -0.71% 6M -0.352% 1Y -57.2%
Confidence100%
No promoter pledgeReasonable PB valuation
Weak ROEThin margins
#241
View details ➜
B
Beta Drugs Ltd
Score 48/100• Decent
Beta Drugs Ltd shows potential but faces challenges in growth consistency and market sentiment.
Company’s Health94/100
Valuation 20/100 · PB 9.5009
Technical Avoid
1M -2.342% 6M 9.436% 1Y 1.628%
Confidence100%
No promoter pledgeDecent revenue growth
#242
View details ➜
B
Beryl Drugs Ltd
Score 48/100• Risky
Beryl Drugs Ltd presents a risky investment with moderate growth potential but significant challenges in profitability and valuation.
Company’s Health59/100
Valuation 80/100 · PB 1.2829
Technical Avoid
1M 4.541% 6M 22.916% 1Y -34.272%
Confidence100%
Low leverage (D/E)No promoter pledge
Weak ROEThin margins
#243
View details ➜
A
Auro Laboratories Ltd
Score 48/100• Decent
Auro Laboratories Ltd shows potential but faces challenges in growth consistency and market valuation.
Company’s Health53/100
Valuation 60/100 · PB 2.8037
Technical Avoid
1M -23.816% 6M -21.518% 1Y -22.541%
Confidence100%
No promoter pledgeReasonable PB valuation
Weak ROE
#244
View details ➜
A
Astrazeneca Pharma India Ltd
Score 48/100• Decent
Astrazeneca Pharma India Ltd shows potential for growth but faces challenges in profitability and valuation metrics.
Company’s Health90/100
Valuation 20/100 · PB 31.0086
Technical Avoid
1M 3.946% 6M 14.144% 1Y 25.313%
Confidence100%
Low leverage (D/E)No promoter pledge
Thin margins
#245
View details ➜
A
Astonea Labs Ltd
Score 48/100• Risky
Astonea Labs Ltd presents several risks with inconsistent growth and profitability metrics, making it a risky investment at this time.
Company’s Health79/100
Valuation 20/100 · PB 13.1607
Technical Avoid
1M -7.35% 6M 10.579% 1Y 10.579%
Confidence100%
No promoter pledgeDecent revenue growth
High debt/equityThin margins
#246
View details ➜
A
Astal Laboratories Ltd
Score 48/100• Risky
Astal Laboratories Ltd shows potential but faces significant risks and challenges in growth and profitability.
Company’s Health74/100
Valuation 60/100 · PB 2.8642
Technical Watch
1M 18.154% 6M 12.543% 1Y -4.546%
Confidence100%
Low leverage (D/E)No promoter pledge
#247
View details ➜
P
Pharmaids Pharmaceuticals Ltd
Score 48/100• Decent
Pharmaids Pharmaceuticals Ltd shows potential in a growing sector, but faces challenges in growth consistency and valuation metrics.
Company’s Health58/100
Valuation 40/100 · PB 3.1724
Technical Avoid
1M -13.618% 6M -26.966% 1Y 0.876%
Confidence100%
No promoter pledgeDecent revenue growth
Weak ROEThin margins
#248
View details ➜
P
Parabolic Drugs Ltd
Score 48/100• Risky
Parabolic Drugs Ltd presents several risks with limited growth prospects and high valuation concerns, making it a risky investment.
Company’s Health14/100
Valuation 100/100 · PB -0.0398
Technical Avoid
1M 0% 6M 0% 1Y 0%
Confidence100%
Reasonable PB valuation
Promoter pledge presentThin margins
#249
View details ➜
O
Oxygenta Pharmaceutical Ltd
Score 48/100• Risky
Oxygenta Pharmaceutical Ltd shows potential but faces significant risks and challenges in the current market environment.
Company’s Health71/100
Valuation 100/100 · PB -9.4091
Technical Avoid
1M -11.718% 6M -26.788% 1Y -35.192%
Confidence100%
No promoter pledgeDecent revenue growth
Thin margins
#250
View details ➜
O
Orchid Pharma Ltd
Score 48/100• Risky
Orchid Pharma Ltd presents several risks with inconsistent growth and high debt levels, making it a risky investment.
Company’s Health72/100
Valuation 60/100 · PB 2.9068
Technical Avoid
1M 0.752% 6M -8.486% 1Y -50.18%
Confidence100%
Low leverage (D/E)No promoter pledge
Weak ROE
#251
View details ➜
N
Novelix Pharmaceuticals Ltd
Score 48/100• Risky
Novelix Pharmaceuticals Ltd presents several risks with inconsistent growth and profitability metrics, alongside valuation concerns.
Company’s Health63/100
Valuation 40/100 · PB 4.8819
Technical Momentum
1M 33.983% 6M 99.361% 1Y 130.652%
Confidence100%
Low leverage (D/E)No promoter pledge
Weak ROEThin margins
#252
View details ➜
N
Norris Medicines Ltd
Score 48/100• Risky
Norris Medicines Ltd presents several risks with inconsistent growth and profitability metrics, making it a risky investment at this time.
Company’s Health37/100
Valuation 100/100 · PB -1.0633
Technical Avoid
1M -2.182% 6M -3.423% 1Y -7.71%
Confidence100%
No promoter pledgeReasonable PB valuation
Thin margins
#253
View details ➜
N
Nexus Surgical and Medicare Ltd
Score 48/100• Risky
Nexus Surgical and Medicare Ltd presents several risks with inconsistent growth and profitability metrics, making it a risky investment at this time.
Company’s Health80/100
Valuation 20/100 · PB 9.3539
Technical Watch
1M 6.702% 6M 25.572% 1Y 3.307%
Confidence100%
Low leverage (D/E)No promoter pledge
#254
View details ➜
M
Morepen Laboratories Ltd
Score 48/100• Risky
Morepen Laboratories Ltd presents several risks with inconsistent growth and profitability metrics, alongside governance concerns.
Company’s Health75/100
Valuation 60/100 · PB 2.1965
Technical Avoid
1M 0.291% 6M -19.71% 1Y -40.436%
Confidence100%
Low leverage (D/E)No promoter pledge
Weak ROEThin margins
#255
View details ➜
Showing 241 to 255 of 301 (21 Pages)